Interim results from a Phase 3 trial of a respiratory syncytial virus (RSV) vaccine candidate for older adults have shown the treatment to be effective with no unexpected safety concerns, the developer GlaxoSmithKline Plc announced on 10 June. The vaccine contains a recombinant subunit prefusion RSV F glycoprotein antigen combined with an adjuvant. The adjuvant, AS01, is proprietary to GSK and is used with several of the company’s other products.
